Graves' disease and hyperthyroidism trials in China

In China 33 Also abroad 93

24 of 33 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Clinical Study of Cizutamig in Thyroid Eye Disease
Where
Beijing, Changsha, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Shanghai, Shenyang, Wuhan
Age
18 years to 75 years
People
38
Run by
Candid Therapeutics
See details and how to joinNCT07597200
Phase 4Taking people
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
Where
Shanghai
Age
18 years to 80 years
People
92
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07265258
Phase 3Not yet taking people in China
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease
Where
Shanghai
Age
18 years to 70 years
People
60
Run by
Beijing Kanghong Biological Medicine Co., Ltd.
See details and how to joinNCT07720635
Phase 3Not yet taking people in China
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease
Where
Shanghai
Age
18 years to 70 years
People
117
Run by
Beijing Kanghong Biological Medicine Co., Ltd.
See details and how to joinNCT07720648
Phase 1Taking people
A Study of IBI3031 in Participants With Thyroid Eye Disease
Where
Shenyang
Age
18 years to 75 years
People
66
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07622368
Phase 2Not yet taking people in China
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
Where
Guangzhou
Age
18 years to 65 years
People
60
Run by
Sun Yat-sen University
See details and how to joinNCT07594912
Phase 2Taking people
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Where
Xiamen
Age
18 years to 75 years
People
8
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07547930
Phase 3Taking people
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Where
Shanghai
Age
18 years to 75 years
People
258
Run by
Minghui Pharmaceutical (Hangzhou) Ltd
See details and how to joinNCT07262476
Early phase 1Taking people
In Vivo CAR-T for Refractory Graves' Disease
Where
Shanghai
Age
18 years to 75 years
People
5
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07333677
No phaseTaking people
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
Where
Beijing
Age
18 years to 80 years
People
50
Run by
Peking University Third Hospital
See details and how to joinNCT07423013
Phase 1Taking people
A Study of GensSci098 in Subjects With Graves' Disease
Where
Shenyang
Age
18 years and over
People
24
Run by
Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT07286656
Phase 1Taking people
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Where
Shanghai
Age
18 years to 75 years
People
76
Run by
Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT06569758
Phase 1/2Taking people
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
Where
Beijing
Age
18 years to 88 years
People
600
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07400224
Early phase 1Taking people
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
Where
Shanghai
Age
18 years to 75 years
People
4
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07261345
Phase 3Taking people
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
Where
Shenyang
Age
18 years to 80 years
People
111
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07113262
Phase 4Taking people
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Where
Changhua, Shanghai
Age
18 years to 80 years
People
64
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07152340
Phase 4Taking people
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
Where
Shanghai
Age
18 years to 80 years
People
96
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07152366
Phase 4Taking people
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Where
Shanghai
Age
18 years to 80 years
People
50
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07152392
Early phase 1Taking people
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
Where
Shanghai
Age
18 years to 65 years
People
5
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07129642
No phaseEnrolling by invitation
Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)
Where
Shanghai
Age
25 years to 70 years
People
120
Run by
Zou Junjie
See details and how to joinNCT06693856
Phase 4Taking people
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
Where
Shanghai
Age
18 years to 80 years
People
60
Run by
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
See details and how to joinNCT06927375
No phaseTaking people
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
Where
Beijing
Age
18 years to 80 years
People
50
Run by
Peking University Third Hospital
See details and how to joinNCT06359795
Phase 4Taking people
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
Where
Nanjing
Age
18 years to 65 years
People
240
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05461820
No phaseTaking people
Multi-model Image of Doxycycline in TAO
Where
Guangzhou
Age
18 years to 70 years
People
20
Run by
Sun Yat-sen University
See details and how to joinNCT05112211